Hologic Inc

Hologic Inc(HOLX)の株式分析

$76.010

+0.365 (+0.48%)終値時点

Loading chart…
高値
76.070
始値
76.010
出来高加重平均価格
76.03
出来高
102.03M
時価総額
17.32B
安値
76.000
売買代金
7.76B
EV/EBITDA(TTM)
11.25

Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.

www.hologic.com

AI分析 of Hologic Inc (HOLX)

中立

Hologic Inc (HOLX) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. While the technical indicators are mildly positive, the lack of significant positive catalysts, a recent analyst downgrade, and declining financial metrics suggest a cautious approach. Holding the stock or exploring other opportunities may be more prudent.

アナリスト評価(19)

上値余地 +2.04%
買い
14 買い
5 中立
0 売り
現在: 76.01
安値
76.00
平均
77.56
高値
79.00

Evercore ISI

2026-01-05

目標株価

$78

In Line

BNP Paribas Exane

2025-11-21

目標株価

$79

中立

Morgan Stanley

2025-11-10

目標株価

$76

Equal Weight

Mizuho

2025-10-23

目標株価

$78

中立

Stephens

2025-10-22

目標株価

$76

Equal Weight

バリュエーション指標

Hologic Inc(HOLX)の現在の予想PERは16.36で、5年平均は18.07です。

予想PER

適正
5年平均 P/E
18.07
現在のP/E
16.36
割高
21.06
割安
15.08

予想EV/EBITDA

割安
5年平均 EV/EBITDA
13.43
現在のEV/EBITDA
11.25
割高
15.31
割安
11.56

予想PSR

割安
5年平均 P/S
4.26
現在のP/S
3.53
割高
4.79
割安
3.72

Alphio AI による HOLX の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%HOLX

$90.01

シナリオ価格

基

基本

基本 · 50%HOLX

$75.18

シナリオ価格

弱

弱気

弱気 · 25%HOLX

$64.21

シナリオ価格

HOLX を保有するクジラ

T

Thematics Asset Management

+ を保有HOLX

+5.62%

3か月リターン

M

MIV Asset Management AG

+ を保有HOLX

+5.21%

3か月リターン

L

LMR Partners LLP

+ を保有HOLX

+4.72%

3か月リターン

M

Manulife Asset Management

+ を保有HOLX

+4.45%

3か月リターン

C

Cinctive Capital Management LP

+ を保有HOLX

+3.28%

3か月リターン

H

HBK Investments L.P.

+ を保有HOLX

+3.13%

3か月リターン

イベントタイムライン

2026-06-16 (ET)

13:30:00

Hologic Wins in Germany, Siemens Prohibited from Selling Mammography Systems

2026-04-07 (ET)

09:30:00

Hologic Completes Acquisition by Blackstone and TPG, Valued at Up to $79 per Share

2026-04-06 (ET)

17:20:00

Blackstone and TPG Acquire Hologic, Deal Expected by April 7

17:20:00

Blackstone and TPG to Acquire Hologic, Deal Expected by April 7

ニュース

HOLX のよくある質問 — Alphio AI が回答

Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm. It operates in the Healthcare sector (X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPA industry).

Hologic Inc (HOLX) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. While the technical indicators are mildly positive, the lack of significant positive catalysts, a recent analyst downgrade, and declining financial metrics suggest a cautious approach. Holding the stock or exploring other opportunities may be more prudent.

19 analysts cover HOLX: 14 rate it Buy, 5 Hold and 0 Sell. The average price target is 77.56.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める